Welcome to our dedicated page for AMERICAN VANGUARD SEC filings (Ticker: AVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
American Vanguard Corporation's SEC filings document the formal disclosures of a NYSE-listed specialty agriculture products company and its AMVAC Chemical Corporation operating subsidiary. Recent Form 8-K reports cover operating results, earnings-call materials, Regulation FD disclosures and material credit arrangements, including term-loan and revolving-credit amendments tied to the company's capital structure and working-capital needs.
Proxy and annual-meeting filings address board elections, director composition, auditor ratification, executive compensation and shareholder voting matters. The filings also identify the company's common stock, par value, exchange listing and governance actions related to board size and committee-level oversight.
American Vanguard Corp senior vice president Jared Straley received a grant of options to buy 20,000 shares of common stock. The incentive stock options have an exercise price of $2.51 per share, vest in full on the third anniversary of the June 4, 2026 grant, and expire on June 4, 2036.
American Vanguard Corp CHRO Shirin Khosravi received a grant of options to buy 20,000 shares of common stock. These incentive stock options have an exercise price of $2.51 per share and relate to 20,000 underlying common shares.
The options vest in full on the third anniversary of the June 4, 2026 grant date and expire on the tenth anniversary, June 4, 2036. Following this award, Khosravi holds options to acquire 20,000 shares directly, reflecting a compensation-related equity grant rather than an open-market purchase or sale.
AMERICAN VANGUARD CORP senior vice president of manufacturing Gilliam Nolteanous received a grant of stock options. The award covers 20,000 options to buy common stock at an exercise price of $2.51 per share.
These incentive stock options vest in full on the third anniversary of the June 4, 2026 grant date and expire on the tenth anniversary, June 4, 2036. Following this grant, Nolteanous holds 20,000 options directly, reflecting compensation rather than an open-market share purchase.
AMERICAN VANGUARD CORP officer Timothy J. Donnelly received a grant of options covering 20,000 shares of common stock. The options have an exercise price of $2.51 per share and were reported as a direct holding.
These incentive stock options vest in full on the third anniversary of the grant date and expire on the tenth anniversary of the grant date. The grant is categorized as a compensation-related acquisition, with no open-market buying or selling of common shares reported in this filing.
Macicek Steven D reported acquisition or exercise transactions in this Form 4 filing.
American Vanguard Corp director Steven D. Macicek reported an equity award of 31,872 deferred stock units (DSUs) of common stock. The units were granted at no cash cost as part of the company’s compensation program for non‑management directors in connection with the 2026 annual stockholders’ meeting.
Each DSU represents the right to receive one share of common stock upon settlement, which occurs when Macicek’s board service ends, upon a change of control, or upon his death. After this grant, he directly holds 80,711 shares or share-equivalent units. DSUs are nontransferable during service and carry neither voting nor dividend rights until they settle.
American Vanguard Corp director Mark R. Bassett received a grant of 31,872 deferred stock units (DSUs) of common stock as part of the company’s 2026 non-management director compensation program. Following this award, he directly holds 89,919 shares or DSUs in total. Each DSU converts into one common share upon settlement when his board service ends, upon a change of control, or upon his death, and carries no voting or dividend rights while outstanding.
Angelini Marisol reported acquisition or exercise transactions in this Form 4 filing.
American Vanguard Corp director Marisol Angelini received a stock grant. She was awarded 31,872 shares of Common Stock at no cash cost as part of the Company's compensation program for non-management directors in connection with the 2026 annual stockholders' meeting. Following this award, she directly holds 68,762 shares of American Vanguard common stock.
American Vanguard Corp director Patrick E. Gottschalk reported an open-market purchase of 25,000 shares of Common Stock at $2.70 per share. After this transaction, his directly held position increased to 191,705 shares, signaling a larger personal stake in the company.
AMERICAN VANGUARD CORP director Patrick E. Gottschalk bought 40,000 shares of Common Stock in the open market across two days. He purchased 20,000 shares on May 12 at $2.92 per share and 20,000 shares on May 13 at $2.95 per share. Following these transactions, he directly holds 166,705 shares of AMERICAN VANGUARD CORP common stock.
American Vanguard Corporation reported improved but still negative results for the quarter ended March 31, 2026. Net sales rose 7% to $123,568, led by 17% growth in U.S. crop and 6% growth in U.S. Specialty, while International sales fell 7%.
Gross profit increased 27% to $38,417, lifting gross margin to 31% from 26%. Operating expenses grew 6% to $36,528, including $2,804 of transformation costs and $659 of asset impairments tied to restructuring the Los Angeles plant. Net loss narrowed to $4,145 (basic and diluted loss per share of $0.14) from $8,462.
The company refinanced its credit facility with two term loans totaling $285,000, raising total debt (net of discounts and costs) to $266,634 and pushing quarterly interest expense to $5,790 at a 10.9% average rate. New covenants require minimum cash balances and restrict dividends and share repurchases. Management highlights geopolitical risks from war in the Middle East that could pressure growers’ costs and demand.